Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat

Thrombosis and Haemostasis

Volumn 78, Issue 5, 1997, Pages 1404-1407

  Eriksson, B I ^a,d   Carlsson, S ^b   Halvarsson, M ^c   Risberg, B ^c   Mattsson, C ^b  

^a Department of Orthopaedics ^*  (Sweden)

^b Preclinical Research   (Switzerland)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d University Hospitals   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; HEPARIN FRAGMENT; INOGATRAN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRIN; THROMBIN INHIBITOR; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAVA VEIN; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; GRAVIMETRY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBOGENESIS; VEIN THROMBOSIS; VENOUS STASIS;

EID: 0030771611     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1665419     Document Type: Article

References (16)

1. Bacher P, Walenga JM, Iqbal O, Bajusz S, Breddin K, Fareed J. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. Thromb Res 1993; 71: 251-63.
2. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-6.
3. 1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb Haemost 1994; 71: 214-9.
4. Wessier S, Reimer M, Sheps M. Biologic assay of thrombosis inducing activity in human serum. J Appl Physiol 1957; 14: 943-6.
5. Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Haemost 1985; 11: 155-75.
6. Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-74.
7. Kumada T, Ishirara M, Ogawa H, Abiko Y. Experimental model of venous thrombosis in rats and effects of some agents. Thromb Res 1980; 18: 189-203.
8. Hladovec JA. A sensitive model of thrombosis in rats. Thromb Res 1986; 43: 539-44.
9. Björk C, Bergqvist D, Esquivel CO, Nilsson B, Rudsvik Y. Effect of heparin, low molecular weight heparin and a heparin analogue on experimental venous thrombosis in the rabbit. Acta Chir Scand 1984; 150: 629-33.
10. Amar J, Caranobe C, Petitou M. Siè P, Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: An experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990; 76: 94-100.
11. Millet J, Theveniaux J, Pascal M. A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations. Thromb Res 1987; 45: 123-33.
12. Mathiasson SE, Lindblad B, Mätzsch T, Holst J, Bergqvist D. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. Thromb Haemost 1994; 71: 363-5.
13. Gustafsson D, Antonsson T, Bylund R, Deinum J, Elg M, Eriksson U, Gyzander E, Karlsson O, Nilsson A, Mattsson C, Pehrsson S, Sörensen H. Melagatran, a new low molecular weight thrombin inhibitor. Effects on thrombin and fibrinolytic enzymes. Thromb Haemost 1997; 8; 79 (in press).
14. Gustafsson D, Elg M, Lenfors S, Börjesson I, Teger-Nilsson A-C. Effects of inogatran, a new low molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis 1996; 7: 69-79.
15. Schumacher WA, Heran CL, Steinbacher TE. Low-Molecular-Weight heparin (Dalteparin) and thrombin Active-site inhibitor (Argatroban) compared in experimental arterial and venous thrombosis and bleeding time. Journal of Cardiovascular Pharmacology 1996; 28: 19-25.
16. Das SK, Cohen AT, Edmonson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus Warfarin for prevention of recurrent venous thromboemnbolism: A randomized trial. World J Surg 1996; 20: 521-7.